|Scientific Subdivisions | The Journal of Molecular Diagnostics
Contact AMP | Sign In | Join / Renew | Go To CHAMP
AMP maintains a transparent standard of practice for publication of AMP documents of all types.Documents arise both formally and informally within the structure of AMP and are generally of the following types:
The result of projects that originate within AMP, i.e. as Subdivision, Committee, Task Force, or Working Group projects, and therefore are "AMP-Owned Documents," subject to the process outlined in the "Guidelines for Publication of AMP-Owned Documents" section below.
The result of projects that arise within an organization outside of AMP, but that eventually involve AMP representation by invitation of one of the original authors or project organizers. These publications are subject to the process outlined in the "Guidelines for Publication of Documents Arising Outside of AMP but Involving an AMP Committee, Subdivision, or Liaison" section below.
The result of an invitation by the Publication & Communication Committee (hereafter PCC) for an AMP member(s) to write an article for a non-peer reviewed journal or magazine as part of an agreement or understanding established between AMP and the publication. These publications are subject to the process outlined in the "Guidelines for Publication of Documents
in Non-peer Reviewed Journals or Publications Arising by Way of Invitation from the Publication & Communication Committee or other AMP Group" section below.
AMP will seek to have all AMP documents freely available, i.e., available immediately to nonsubscribers, to the extent AMP can control this.
1. Documents, manuscripts, and their derivative works generated by AMP committees or their respective workgroups and/or task forces are considered to be AMP-owned documents. Substantial contributors will be named as authors or appropriately acknowledged.
2. AMP will be the "owner" of the documents, manuscripts prior to publication, and their derivative works. Owners of publications own the copyright to the published work.
3. AMP will pay for any submission, page and publication charges.
4. When a project that originates within AMP intends to have as a product a report or manuscript, the following considerations should be understood and the following steps should be taken at the outset:
a. The project is the responsibility of the AMP group (i.e. Committee or Subdivision) and not the responsibility of individual members.
b. Non-AMP members should not be involved in AMP Committee or Subdivision Reports or Position Statements without the approval of the Board of Directors. Committees or subdivisions may involve non-AMP members in manuscripts that report a scientific study (e.g. manuscript from an AMP Working Group).
c. Where appropriate to the project, all authors will agree to comply with the terms of both a project-specific Commitment Letter and a Confidentiality and Intellectual Property Agreement prior to joining the project.
d. The Committee or subdivision Chair should designate a specific member to be in charge of the project ("Project Coordinator"), which can be him/her self.
e. The Project Coordinator will, with staff assistance, prepare a Project Plan to include:
- Recommended publication type: e.g., sent to AMP members as a membership benefit, published directly to AMP website, or submission to a peer-reviewed journal. If the document is intended as a peer-reviewed journal publication, it is expected that it be submitted to AMP's journal, The Journal of Molecular Diagnostics (JMD). If the AMP group responsible for the project believes another journal has a more appropriate audience for the particular project, justification should be provided in the Project Plan for consideration by the Board of Directors.
- Budget: estimated costs associated with the report, e.g., data analysis, data collection, and publication costs, i.e., page, figure/table charges, if applicable. AMP does not order reprints.
- Abstract or project description: includes an estimate of length
f. The chair of the AMP group responsible for the project will submit the Project Plan to the Executive Committee for approval prior to beginning the project. The Executive Committee should consider the proposal at its next scheduled meeting.
5. Should the Project Coordinator's term of office terminate before completion of the project, the current Committee Chair will determine if it is appropriate for the Project Coordinator to see the project through to completion, and seek appointment of the Project Coordinator as an ad hoc member of the Committee, or if a new committee member should be designated as the Project Coordinator. The Committee Chair will also determine if other committee members who have been involved in the project and whose terms of office are completed should become ad hoc members to continue working on the project, or whether new committee members should be assigned.
6. Title / Author list / Disclaimer Guidelines:
a. Manuscripts that are Committee Reports or Position Statements will have "A Report (or Statement) of the Association for Molecular Pathology" at the beginning or the end of the title.
b. Authors will be listed as members of the AMP Working Group or Task Force and with their primary institutional affiliation.
c. Author listings will comply with the AMP Selection of Authors & Conflicts of Interest for AMP Reports/Manuscripts Policy.
d. Working Group or Task Force manuscripts will list the names of the sponsoring committee for the time period encompassing the project, e.g., Clinical Practice Committee, immediately below the list of Working Group or Task Force authors.
e. All manuscripts relating to clinical practice, including Practice Guidelines, should contain an appropriate disclaimer in a footnote on the first page, e.g., "Standard of practice is not being defined, and that there may be alternatives."
7. Upon completion of the document, the Project Coordinator will:
a. Utilize the Selection of Authors & Conflicts of Interest for AMP Reports/Manuscripts Policy, to decide whether specific contributors should have authorship or be acknowledged, and, if so, in what order.
b. Draft a cover letter to the Editor of the journal (e.g. JMD). The cover letter should designate the person who will correspond with the editor. This person ("Corresponding Author") should be the Project Coordinator, but the Project Coordinator may designate another author.
8. The Project Coordinator will initiate the AMP internal review process by contacting the AMP staff for the project, and identifying or supplying the final manuscript and letter to the Editor where appropriate.
a. It should be clearly understood that the review process will involve approval by more than one group of AMP members and that all AMP reviewers should treat the document as confidential. Internal AMP reviewers should understand that they are not "substantial contributors" and that they will not receive any particular recognition or acknowledgment upon publication.
b. It should be clearly understood by all authors that the AMP internal review process is not a substitute for or equivalent to the journal's peer-review process. Instead, AMP internal review ensures broadly that the scientific content is of appropriate quality (subject matter expert review) and that the manuscript is appropriate to be identified as an AMP report or statement (Executive Committee review).
c. Final review and organizational approval of the manuscript and letter must be completed by the AMP Executive Committee prior to submission of the manuscript to the Journal by the Project Coordinator or corresponding author.
d. AMP staff will provide the Project Coordinator and corresponding author a copy of the current AMP internal review process.
9. The Project Coordinator is responsible for submitting the approved manuscript and cover letter to the journal.
a. During peer review by the journal, the reviewers may require suggested revisions. The corresponding author will keep the Project Coordinator, the PCC Chair, and the AMP staff member informed of all correspondence with the Journal Editorial staff.
b. Journal Editorial staff will send a copy of the submitted manuscript with revisions to the AMP staff member who will forward it to the PCC Chair. The PCC Chair may require that the revised manuscript receive approval from the PCC Chair before resubmission to the journal for final acceptance.
AMP and AMP members should be visibly and appropriately acknowledged for their contributions to the project and/or resulting publication(s). This acknowledgement of AMP is appropriate because the project involves the resources of AMP, including but not limited to, completion of a survey, contribution to or discussion of the project during committee conference calls, travel support for liaisons, or provision of specific information.
Any use of the AMP name requires approval by the association; therefore, these publications require the review of the PCC Chair in order to ensure AMP's protection from liability or other problems due to the publication's content. The PCC Chair may enlist the assistance of any Subdivision Leadership or Board member in this review. These articles do not require review by the Executive Committee unless AMP's name is used in the title or official endorsement of content by AMP is implied. Preferential consideration of submission to The Journal of Molecular Diagnostics is encouraged but is not required.
AMP members may be invited by the PCC or another AMP group to submit articles for non-peer reviewed journals or publications as part of an agreement or understanding established between AMP and the publication. Such articles are reviewed by the PCC Chair or designee and at least one other member of the Publications Committee. The PCC Chair, or designee, will communicate suggested revisions, if any, to the author(s). The PCC Chair will make the final determination when the document is ready to be sent to the Editor of the journal/publication. Review by the journal/publication Editor may occur simultaneously or subsequent to the PCC review process. These non-peer reviewed articles do not require review by the Executive Committee unless AMP's name is used in the title or official endorsement of content by AMP is implied. Agreements entered between AMP and a publication to provide suitable AMP-member authorship for a series of articles must be approved by the Executive Committee.
In general, publications resulting from a joint collaborative project will be governed by a specific Memorandum of Understanding (MOU) or project description that addresses the individual joint project's publication process and intellectual property considerations. AMP will be included in the title of the publication and any derivative works. AMP members contributing to this effort will be listed as authors or otherwise appropriately acknowledged in the publication and any derivative works. This acknowledgement of AMP and AMP members is appropriate because the project involves the resources of AMP, including but not limited to, contribution to or discussion of the project during committee conference calls, provision of specific information, and financial support for the project's development. Any use of the AMP name requires approval by the Association; therefore, these publications require the review of the PCC Chair and Executive Committee in order to ensure AMP's protection from liability or other problems due to the publication's content. The PCC Chair may enlist the assistance of any Subdivision Leadership or Board member in this review. Concurrent reviews by the PCC Chair and Executive Committee are permitted but not required. Co-publication of the approved manuscript in JMD and other participating organization's journals is to be sought in the MOU or project description, and will include a stipulation that the published manuscript be freely accessible to non-subscribers. If the approved manuscript is not co-published, preferential consideration of submission to JMD is required when the project is initiated by AMP. Otherwise, publication in JMD is encouraged but is not required.
When an organization and/or project group arising outside of AMP seeks endorsement of a document by AMP as an organization, the document must be reviewed and approved by both the PCC Chair and the Executive Committee. The PCC Chair may enlist the assistance of any Subdivision Leadership or Board member in this review. Concurrent reviews by the PCC Chair and Executive Committee are permitted but not required. Preferential consideration of submission to The Journal of Molecular Diagnostics is encouraged but is not required.
Do Circulating Tumor Cells, Exosomes and Circulating Nucleic Acids Have Clinical Utility for Molecular Pathologists? A Report of the Association for Molecular Pathology
Bert Gold,1,2 Milena Cankovic,1,3 Larissa V. Furtado,1,4 Frederick Meier,1,3 and Christopher D. Gocke1,5
1The CTC Working Group of the Clinical Practice Committee, Association for Molecular Pathology^
2Center for Cancer Research, National Cancer Institute, Frederick, MD
3Department of Pathology, Henry Ford Hospital, Detroit, MI
4Department of Pathology, University of Chicago Medical Center, Chicago, IL
5Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD
^The CTC Working Group is a working group of the Association for Molecular Pathology (AMP) Clinical Practice Committee. The 2013-2014 Clinical Practice Committee consisted of Matthew Bankowski, Milena Cankovic, Jennifer Dunlap, Larissa V. Furtado, Jane S. Gibson, Jerald Z. Gong, Thomas Huard, Linda Jeng, Loren Joseph (Chair 2013-2014), Annette Kim, Marilyn M. Li, Melissa Miller, Mary Lowery Nordberg, Carolyn Sue Richards, Paul Rothberg, M. Fernanda Sabato, and Patrik Vitazka.
Standard of practice is not defined by this article, and there may be alternatives. See Disclaimer for further details.
The AMP Clinical Practice Guidelines and Reports are developed to be of assistance to laboratory and other health care professionals by providing guidance and recommendations for particular areas of practice. The Guidelines or Report should not be considered inclusive of all proper approaches or methods, or exclusive of others. The Guidelines or Report cannot guarantee any specific outcome, nor do they establish a standard of care. The Guidelines or Report are not intended to dictate the treatment of a particular patient. Treatment decisions must be made based on the independent judgment of health care providers and each patientâ€™s individual circumstances. AMP makes no warranty, express or implied, regarding the Guidelines or Report and specifically excludes any warranties of merchantability and fitness for a particular use or purpose. AMP shall not be liable for direct, indirect, special, incidental, or consequential damages related to the use of the information contained herein.
Approved by AMP Board of Directors September 30, 2015